Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta

Laura Negrotto, Ester Cantó, Jordi Río, Mar Tintoré, Xavier Montalban, Manuel Comabella

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

© 2015 Elsevier B.V. CD8 + CD161hi cells, comprising MAIT and non-MAIT cells, have been involved in multiple sclerosis (MS) pathogenesis. Here, we investigated the frequency of CD8 + CD161hi, MAIT and non-MAIT cells by flow cytometry in peripheral blood samples from 41 untreated MS patients, 48 patients receiving disease modifying therapies, and 17 healthy controls (HC). IFNβ treatment was associated with a decrease in the frequency of Tc17 cells compared to untreated patients (p = 0.019). No significant differences were observed between untreated MS patients and HC for any of the study cell populations. These results suggest previously unknown mechanisms of action of IFNβ.
Original languageEnglish
Pages (from-to)98-101
JournalJournal of Neuroimmunology
Volume288
DOIs
Publication statusPublished - 1 Jan 2015

Keywords

  • CD161
  • CD8+CD161hi
  • Immunomodulatory treatments
  • Interleukin-17
  • Mucosal-associated invariant T cells
  • Multiple sclerosis
  • Tc17

Fingerprint Dive into the research topics of 'Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta'. Together they form a unique fingerprint.

Cite this